.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,803,838

« Back to Dashboard

Claims for Patent: 7,803,838

Title:Compositions comprising nebivolol
Abstract: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
Inventor(s): Davis; Eric (Morgantown, WV), O'Donnell; John (Morgantown, WV), Bottini; Peter (Morgantown, WV)
Assignee: Forest Laboratories Holdings Limited (BM)
Application Number:11/141,235
Patent Claims: 1. A composition comprising between about 0.125 mg to about 40 mg nebivolol or a pharmaceutically acceptable salt thereof and between about 1 mg to about 1200 mg of an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, losartan, valsartan and pharmaceutically acceptable salts thereof wherein the composition provides a higher therapeutic index when administered to a patient having hypertension than either the corresponding amount of nebivolol or the ARB administered alone.

2. The composition of claim 1 wherein the ARB is olmesartan or a pharmaceutically acceptable salt thereof.

3. The composition of claim 1 wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.

4. The composition of claim 1 wherein the ARB is valsartan or a pharmaceutically acceptable salt thereof.

5. A composition comprising between about 0.125 mg to about 40 mg nebivolol or a pharmaceutically acceptable salt thereof and between about 1 mg to about 1200 mg of an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, losartan, valsartan and pharmaceutically acceptable salts thereof wherein the effectiveness of the composition when administered to a patient having hypertension is greater than the sum of the nebivolol or the ARB used alone.

6. The composition of claim 5 wherein the ARB is olmesartan or a pharmaceutically acceptable salt thereof.

7. The composition of claim 5 wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.

8. The composition of claim 5 wherein the ARB is valsartan or a pharmaceutically acceptable salt thereof.

9. A composition comprising between about 0.125 mg to about 40 mg nebivolol or a pharmaceutically acceptable salt thereof and between about 1 mg to about 1200 mg of an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, losartan, valsartan and pharmaceutically acceptable salts thereof wherein the composition is at least 100% more effective than treatment with nebivolol or the ARB administered alone.

10. The composition of claim 9 wherein the ARB is olmesartan or a pharmaceutically acceptable salt thereof.

11. The composition of claim 9 wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.

12. The composition of claim 9 wherein the ARB is valsartan or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc